U.S. markets closed

Adagene Inc. (ADAG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.2800+0.0200 (+1.59%)
At close: 04:00PM EDT

Adagene Inc.

Building C14
4th Floor No. 218, Xinghu Street Suzhou Industrial Park
Suzhou 215123
86 512 8777 3632

Full Time Employees259

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter P. Luo Ph.D.Co-Founder, CEO & ChairmanN/AN/A1966
Mr. Man Kin Tam M.B.A.CFO & DirectorN/AN/A1977
Dr. Fangyong Du Ph.D.Chief Technology OfficerN/AN/A1970
Dr. Jc Xu M.D., Ph.D.Chief Scientific OfficerN/AN/A1965
Ms. Ami Celeste KnoeflerVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Ling ZhouHead of HRN/AN/AN/A
Dr. Qinghai ZhaoChief Manufacturing OfficerN/AN/A1961
Ms. Yan Li M.B.A.Sr. VP of Bioinformatics & Information TechnologyN/AN/A1975
Ms. Xiaohong SheSr. VP & Head of Clinical OperationsN/AN/A1967
Dr. Guizhong Liu Ph.D.Head of Biology & PharmacologyN/AN/A1971
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Corporate Governance

Adagene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.